Wells Fargo initiated coverage of Aerovate Therapeutics with an Overweight rating and $35 price target. The firm sees a “high risk, high reward opportunity” in the company’s pulmonary arterial hypertension, or PAH, treatment program.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AVTE:
- Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
- Aerovate completes enrollment for Phase 2b portion of IMPAHCT study
- Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights
- Aerovate Therapeutics reports Q3 EPS (71c), consensus (69c)
- Is AVTE a Buy, Before Earnings?
